AstraZeneca plc (LON:AZN) received a GBX 4,500 ($58.62) target price from S&P Global in a report released on Thursday. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. S&P Global’s target price would indicate a potential downside of 11.99% from the company’s current price.

AZN has been the topic of a number of other reports. Liberum Capital restated a “buy” rating and issued a GBX 5,100 ($66.44) price target on shares of AstraZeneca plc in a report on Thursday, April 27th. Barclays PLC restated an “overweight” rating and issued a GBX 6,000 ($78.17) price target on shares of AstraZeneca plc in a report on Friday, April 28th. Credit Suisse Group restated an “underperform” rating and issued a GBX 4,000 ($52.11) price target on shares of AstraZeneca plc in a report on Wednesday, April 19th. UBS AG set a GBX 5,150 ($67.09) price target on AstraZeneca plc and gave the company a “neutral” rating in a report on Tuesday, June 27th. Finally, Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.81) price target on AstraZeneca plc and gave the company a “sell” rating in a report on Saturday, May 20th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have given a buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of “Hold” and an average target price of GBX 5,251.80 ($68.42).

Shares of AstraZeneca plc (LON:AZN) traded down 15.41% on Thursday, reaching GBX 4325.00. The company’s stock had a trading volume of 10,636,810 shares. The stock’s market cap is GBX 54.75 billion. The company’s 50 day moving average is GBX 5,187.89 and its 200-day moving average is GBX 4,861.95. AstraZeneca plc has a 1-year low of GBX 3,996.00 and a 1-year high of GBX 5,520.00.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/27/astrazeneca-plc-azn-given-a-gbx-4500-price-target-by-sp-global-analysts.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.